CB1 receptors, in general, show an increasing trend when treated with agonists in several cancer morphotypes; however, in normal tissue, these agonists decrease their expression.
← all excerpts
3-Hydroxypropane-1,2-Diyl Dipalmitoleate-A Natural Compound with Dual Roles (CB1 Agonist/FAAH1 Blocker) in Inhibiting Ovarian Cancer Cell Line.
1
—
—